Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction.

Peters BJ, Rodin AS, Klungel OH, Stricker BH, de Boer A, Maitland-van der Zee AH.

Pharmacogenet Genomics. 2010 Dec;20(12):766-74. doi: 10.1097/FPC.0b013e328340aded.

PMID:
21037509
2.

Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant.

Peters BJ, Maitland-van der Zee AH, Stricker BH, van Wieren-de Wijer DB, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, van Duijn CM, Klungel OH.

Pharmacogenet Genomics. 2008 Jul;18(7):631-6. doi: 10.1097/FPC.0b013e3283023fb2.

PMID:
18551043
3.

Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.

Peters BJ, Pett H, Klungel OH, Stricker BH, Psaty BM, Glazer NL, Wiggins KL, Bis JC, de Boer A, Maitland-van der Zee AH.

Atherosclerosis. 2011 Aug;217(2):458-64. doi: 10.1016/j.atherosclerosis.2011.06.023. Epub 2011 Jun 17.

4.

Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.

Peters BJ, Rodin AS, Klungel OH, van Duijn CM, Stricker BH, van't Slot R, de Boer A, Maitland-van der Zee AH.

Pharmacogenomics. 2010 Aug;11(8):1065-76. doi: 10.2217/pgs.10.81.

PMID:
20712525
5.

Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.

Hindorff LA, Lemaitre RN, Smith NL, Bis JC, Marciante KD, Rice KM, Lumley T, Enquobahrie DA, Li G, Heckbert SR, Psaty BM.

Pharmacogenet Genomics. 2008 Aug;18(8):677-82. doi: 10.1097/FPC.0b013e3283033528.

6.

Angiotensin II type I receptor gene and myocardial infarction: tagging SNPs and haplotype based association study. The Beijing atherosclerosis study.

Su S, Chen J, Zhao J, Huang J, Wang X, Chen R, Gu D; Beijing Atherosclerosis Study.

Pharmacogenetics. 2004 Oct;14(10):673-81.

PMID:
15454732
7.

No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.

Leusink M, de Keyser CE, Onland-Moret NC, Hofman A, Visser LE, Stricker BH, de Bakker PI, de Boer A, van Schaik RH, Maitland-van der Zee AH.

Pharmacogenomics. 2014 Aug;15(11):1471-7. doi: 10.2217/pgs.14.90.

PMID:
25303298
8.

Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease.

Baessler A, Fischer M, Mayer B, Koehler M, Wiedmann S, Stark K, Doering A, Erdmann J, Riegger G, Schunkert H, Kwitek AE, Hengstenberg C.

Hum Mol Genet. 2007 Apr 15;16(8):887-99. Epub 2007 Feb 26.

PMID:
17324965
9.

[Association of ADAMTS-1 gene polymorphisms with ischemic stroke caused by large artery atherosclerosis].

Lyu C, Chen Y, Zhu M, Jin X, Liu P, Zheng Z, Li C, Zhu F, Hu X, Wang F, Li W, Wang W.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2015 Dec;32(6):844-8. doi: 10.3760/cma.j.issn.1003-9406.2015.06.021. Chinese.

PMID:
26663063
10.

Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction.

van Wieren-de Wijer DB, Maitland-van der Zee AH, de Boer A, Kroon AA, de Leeuw PW, Schiffers P, Janssen RG, Psaty BM, van Duijn CM, Stricker BH, Klungel OH.

J Hypertens. 2009 Jan;27(1):61-8.

PMID:
19145769
11.
12.

Patterns of statin prescription in acute myocardial infarction: the French registry of Acute ST-elevation or non-ST-elevation Myocardial Infarction (FAST-MI).

Ferrières J, Bataille V, Leclercq F, Geslin P, Ruidavets JB, Grollier G, Bernard P, Cambou JP, Simon T, Danchin N.

Atherosclerosis. 2009 Jun;204(2):491-6. doi: 10.1016/j.atherosclerosis.2008.09.031. Epub 2008 Oct 8.

PMID:
19004441
13.

Chromosome 1p13 genetic variants antagonize the risk of myocardial infarction associated with high ApoB serum levels.

Gigante B, Leander K, Vikström M, Ye S, de Faire U.

BMC Cardiovasc Disord. 2012 Oct 16;12:90. doi: 10.1186/1471-2261-12-90.

14.

Relationship between haplotypes of KCNN4 gene and susceptibility to human vascular diseases in Japanese.

Yamaguchi M, Nakayama T, Fu Z, Naganuma T, Sato N, Soma M, Doba N, Hinohara S, Morita A, Mizutani T.

Med Sci Monit. 2009 Aug;15(8):CR389-97.

PMID:
19644414
15.

Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.

Lin CF, Chang YH, Liu JC, Chuang MT, Chien LN.

BMC Cardiovasc Disord. 2016 Jan 28;16:24. doi: 10.1186/s12872-016-0202-x.

16.

Polymorphisms in the ACE and ADRB2 genes and risks of aging-associated phenotypes: the case of myocardial infarction.

Kulminski AM, Culminskaya IV, Ukraintseva SV, Arbeev KG, Akushevich I, Land KC, Yashin AI.

Rejuvenation Res. 2010 Feb;13(1):13-21. doi: 10.1089/rej.2009.0905.

17.

Effect of drug combinations on admission for recurrent myocardial infarction.

van der Elst ME, Bouvy ML, de Blaey CJ, de Boer A.

Heart. 2007 Oct;93(10):1226-30. Epub 2007 May 13.

18.

Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).

Ojeifo O, Wiviott SD, Antman EM, Murphy SA, Udell JA, Bates ER, Mega JL, Sabatine MS, O'Donoghue ML.

JACC Cardiovasc Interv. 2013 Dec;6(12):1275-81. doi: 10.1016/j.jcin.2013.06.014. Epub 2013 Nov 13.

19.

Genetic variants associated with myocardial infarction and the risk factors in Chinese population.

Wang Y, Wang L, Liu X, Zhang Y, Yu L, Zhang F, Liu L, Cai J, Yang X, Wang X.

PLoS One. 2014 Jan 27;9(1):e86332. doi: 10.1371/journal.pone.0086332. eCollection 2014.

20.

Pharmacogenetic study of statin therapy and cholesterol reduction.

Chasman DI, Posada D, Subrahmanyan L, Cook NR, Stanton VP Jr, Ridker PM.

JAMA. 2004 Jun 16;291(23):2821-7.

PMID:
15199031

Supplemental Content

Support Center